A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva/Gazyvaro) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Latest Information Update: 08 May 2024
At a glance
- Drugs Glofitamab (Primary) ; Obinutuzumab (Primary) ; Tocilizumab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Roche
- 02 May 2024 According to City of Hope media release, data from this study will be presented at ASCO Annual Meeting 2024, which will take place in Chicago from May 31 to June 4.
- 12 Dec 2023 Results assessing mechanisms underlying response and resistance to glofitamab, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Result(As of May 1, 2023, n=145) assessing dose-escalation and expansion cohorts ,presented at the 65th American Society of Hematology Annual Meeting and Exposition